astrazeneca plc-spons adr (AZN) Key Developments
AstraZeneca PLC Presents at The Pharma Summit 2014, Mar-13-2014 03:35 PM
Mar 10 14
AstraZeneca PLC Presents at The Pharma Summit 2014, Mar-13-2014 03:35 PM. Venue: The Dorchester, London, United Kingdom. Speakers: Menelas Pangalos, Executive Vice President of Innovative Medicines & Early Development.
AstraZeneca Launches Healthcare Research Fund in Nigeria
Mar 7 14
AstraZeneca has launched a Nigerian research fund. The fund will reportedly total USD 300,000, with funding directed towards research aimed at improving health data collection and monitoring in the country. Specifically, AstraZeneca will reportedly seek to invest in five to seven projects each year in areas such as prevalence/epidemiology, pharmaco-economics, and outcomes research. Key to the research agenda will be research into non-communicable diseases.
AstraZeneca Business Development Presents at 8th Annual BIO Europe Spring 2014, Mar-10-2014 09:00 AM
Mar 7 14
AstraZeneca Business Development Presents at 8th Annual BIO Europe Spring 2014, Mar-10-2014 09:00 AM. Venue: OVAL Lingotto, Turin, Italy. Speakers: John Easton, Head, Business Operations.
AstraZeneca Announces U.S. Food and Drug Administration Approves Bydureon(R) Pen for Once-Weekly Treatment of Adults with Type 2 Diabetes
Mar 3 14
AstraZeneca announced that the U.S. Food and Drug Administration has approved the Bydureon Pen (exenatide extended-release for injectable suspension) 2 mg as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Bydureon should not be used for treatment of patients with type 1 diabetes or diabetic ketoacidosis. Bydureon is not recommended as first-line therapy for patients who have inadequate glycemic control on diet and exercise. Bydureon is not a substitute for insulin. The concurrent use of Bydureon with insulin has not been studied and is not recommended. Bydureon is the first and only once-weekly medicine for adults with type 2 diabetes. The Bydureon Pen is a pre-filled, single-use pen injector, eliminating the need for the patient to transfer the medication between a vial and syringe during the self-injection process. The Bydureon Pen contains the same formulation and dose as the original Bydureon single-dose tray, providing the same continuous release of exenatide. Bydureon has been shown to provide powerful HbA1c reduction. In a 24-week, randomized, open-label trial, once-weekly Bydureon demonstrated an HbA1c reduction of 1.6 percentage points vs 0.9 percentage points for twice-daily Byetta injection at 24 weeks. Additionally, Bydureon demonstrated a mean weight reduction of 5.1 pounds vs 3.1 pounds with Byetta. Bydureon is not indicated for the management of obesity, and weight change was a secondary endpoint in clinical trials.
AstraZeneca Announces the US Food and Drug Administration Approved Orphan Drug Myalept
Feb 25 14
AstraZeneca announced the US Food and Drug Administration approved orphan drug MYALEPT™, which is indicated as an adjunct to diet as replacement therapy for the treatment of complications of leptin deficiency in patients with congenital or acquired generalised lipodystrophy. MYALEPT, a recombinant analogue (laboratory-created form) of human leptin, is the first and only treatment approved by the FDA for these patients. AstraZeneca is working to complete the transfer of the Biologics License Application (BLA) for MYALEPT from Bristol-Myers Squibb Company to AstraZeneca as part of the acquisition of the diabetes alliance assets, including MYALEPT and Amylin Pharmaceuticals, which was completed on February 1, 2014.